Review



peripheral blood cd4 + t lymphocytes  (BioIVT Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioIVT Inc peripheral blood cd4 + t lymphocytes
    C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or <t>cynomolgus</t> monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
    Peripheral Blood Cd4 + T Lymphocytes, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peripheral+blood+cd4+++t+lymphocytes/peripheral+blood+cd4+++t+lymphocytes/pmc09414278-115-39-47
    Average 90 stars, based on 1 article reviews
    peripheral blood cd4 + t lymphocytes - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents"

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

    Journal: Cancer Immunology Research

    doi: 10.1158/2326-6066.CIR-21-0031

    C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
    Figure Legend Snippet: C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

    Techniques Used: Blocking Assay, Enzyme-linked Immunosorbent Assay, Incubation, Recombinant, Concentration Assay, Binding Assay, Control

    Related Articles

    Binding Assay:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Flow Cytometry:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Blocking Assay:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Incubation:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Recombinant:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Concentration Assay:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.

    Control:

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Article Title: Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
    Article Snippet: PBMCs CD3+ T cells CD4+ T cells CD8+ T cells B cells NK cells Monocytes Donor #13 (Red Cross/FcγRIIIA genotype unknown) 53.9% 44.8% 7.7% 5.3% 22.1% 9.8% Donor #14 (RedCross/FcγRIIIA genotype unknown) 58.9% 42.8% 12.7% 2.1% 22.5% 8.8% Donor # CC00087 (Bio-IVT/FcγRIIIA genotype V158/V158) 50.4% 30.4% 16.0% 7.4% 7.0% 24.7% Supplementary Figure S2 Supplementary Figure S2 continued Supplementary Figure S2.



    Similar Products

    peripheral blood cd4 + t lymphocytes  (BioIVT Inc)
    90
    BioIVT Inc peripheral blood cd4 + t lymphocytes
    C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or <t>cynomolgus</t> monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
    Peripheral Blood Cd4 + T Lymphocytes, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peripheral+blood+cd4+++t+lymphocytes/peripheral+blood+cd4+++t+lymphocytes/pmc09414278-115-39-47
    Average 90 stars, based on 1 article reviews
    peripheral blood cd4 + t lymphocytes - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

    Journal: Cancer Immunology Research

    Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

    doi: 10.1158/2326-6066.CIR-21-0031

    Figure Lengend Snippet: C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

    Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

    Techniques: Blocking Assay, Enzyme-linked Immunosorbent Assay, Incubation, Recombinant, Concentration Assay, Binding Assay, Control